Back to News
Market Impact: 0.28
BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser
Source: zacks.com
Healthcare & BiotechProduct LaunchesRegulation & Legislation
Bausch + Lomb received European CE Mark approval for SeeLyra, a compact laser platform for cataract and corneal procedures. The approval expands the company’s surgical portfolio and enables commercialization in applicable European markets, supporting its ophthalmic-device growth strategy.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.48
Ticker Sentiment
BLCO0.72
More News
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%
- BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE
- What Bausch + Lomb (BLCO) Said on Its Q3 Earnings Call
- Google's Gemini 4 Carbon looks like a diamond in the rough
- Healey Defends UK Budget, Warns 'Tough Decisions' Ahead
- Kalshi, co-founders hit with criminal charges in US state of Utah